Cetrimide
drugOn this page
Also known as AnglianBactrianBansorCeanelCetavlexCetavlonCetavlon pcCetrimidaCetrimide bromideCetrimidesCetrimidumCetrimonium hydroxideCradocapLissolamine vMedicaidQuammoniumRichmondSuticideToracsol
Summary
Cetrimide (CHEMBL5219790) is an approved unknown (ATC D11AC01); indicated across 1 condition including injury.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Unknown
- ATC class: D11AC01 (+1 more)
- Indications: 1 condition
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL5219790 |
| Name | Cetrimide |
| Type | Unknown |
| Max phase | 4 |
| ATC | D11AC01, D08AJ04 |
Also known as: Anglian, Bactrian, Bansor, Ceanel, Cetavlex, Cetavlon, Cetavlon pc, Cetrimida, Cetrimide, Cetrimide bromide, Cetrimides, Cetrimidum
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Nuclear receptor ROR-gamma, 4’-phosphopantetheinyl transferase ffp, Dynamin-1, Huntingtin.
Bioactivity
ChEMBL activities: 2 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| P51450 | 5.5 | Potency | 3162 | nM | CHEMBL_ACT_4818463 |
| DNM1 | 5.24 | IC50 | 5790 | nM | CHEMBL_ACT_395812 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| injury | 2 | MONDO:0021178 | EFO:0000546 |
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 5 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02657499 | Not specified | COMPLETED | Post Affordable Care Act Evaluation |
| NCT02685384 | Not specified | COMPLETED | Post ACA Reform: Evaluation of Community Health Center Care of Diabetes |
| NCT02936609 | Not specified | COMPLETED | Assessing Community Cancer Care After Insurance ExpanSionS |
| NCT03545763 | Not specified | COMPLETED | Evaluating Control of Hypertension - Effect of Social Determinants |
| NCT05319743 | Not specified | COMPLETED | Evaluating Quality and Value of US Ambulatory Care Delivered Among Medicaid Expansion/Non-Expansion States, 2012-2015 |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.